Post-Stroke Aphasia and Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment Study
NCT ID: NCT01512264
Last Updated: 2020-07-14
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
28 participants
INTERVENTIONAL
2012-01-31
2018-07-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exploration of Repeated High-frequency Transcranial Magnetic Stimulation for the Treatment of Acute Phase Aphasia in Post-stroke Patients
NCT06787508
Speech Therapy and Repetitive Transcranial Magnetic Stimulation Therapy in Post-stroke Anomic Aphasia
NCT04625790
Dual Hemisphere rTMS for Rehabilitation of Post Stroke Aphasia
NCT01850836
Effects of rTMS Based on Neural Activation in Language Performance in Stroke Patients With Non-fluent Aphasia
NCT02591719
Post-Stroke Aphasia TMS
NCT06974279
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To fill the gap in our therapeutic arsenal for aphasia, we propose a study with the following specific aims: (1) to determine the comparative efficacy and optimal dosing of nerTMS on aphasia recovery using a randomized, double-blind, sham-controlled study design. Subjects (15/group) will be randomly assigned to 4 treatment groups: (a) 3 weeks of nerTMS, (b) 1 week of ST + 2 weeks of nerTMS, (c) 2 weeks of ST +1 week of nerTMS, or (d) 3 weeks of ST (control group). This design will allow systematic evaluation of the efficacy of nerTMS and will determine its most optimal dose for language recovery. Short- and long-term outcomes will be evaluated with aphasia testing (AT) and fMRI; (2) to use fMRI to assess changes in language lateralization in response to nerTMS. We will examine the relationship between the degree of pre-nerTMS language lateralization (fMRI) with the post-nerTMS language outcomes (AT) and determine whether fMRI language lateralization can predict AT performance following nerTMS targeted to the left middle cerebral artery (LMCA) stroke areas.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
rTMS
3 weeks of nerTMS
Magstim SuperRapid
This design will allow systematic evaluation of the efficacy of nerTMS and its most optimal dose for language recovery.
1 week of Sham Treatment + 2 weeks of nerTMS
1 week of Sham Treatment + 2 weeks of nerTMS
Magstim SuperRapid
This design will allow systematic evaluation of the efficacy of nerTMS and its most optimal dose for language recovery.
2 weeks of Sham Treatment +1 week of nerTMS
2 weeks of Sham Treatment +1 week of nerTMS
Magstim SuperRapid
This design will allow systematic evaluation of the efficacy of nerTMS and its most optimal dose for language recovery.
Control Group
3 weeks of Sham Treatment
Magstim SuperRapid
This design will allow systematic evaluation of the efficacy of nerTMS and its most optimal dose for language recovery.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Magstim SuperRapid
This design will allow systematic evaluation of the efficacy of nerTMS and its most optimal dose for language recovery.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* LMCA stroke as indicated by the presence of aphasia and MRI lesion in the LMCA distribution
* Moderate aphasia (Token Test score between 40th and 90th percentile)
* Fluency in English
* Provision of written informed consent by the patient and/or the next of kin
Exclusion Criteria
* Underlying degenerative or metabolic disorder or supervening medical illness
* Severe depression or other psychiatric disorder
* Positive pregnancy test in women of childbearing age
* Any contraindication to MRI/fMRI at 3T (i.e., intracranial metal implants, claustrophobia)
* Any contraindication to nerTMS (e.g., seizures or epilepsy)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
University of Alabama at Birmingham
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jerzy P Szaflarski
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jerzy P Szaflarski, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Alabama at Birmingham
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.